Sub-analysis from the SELECT Trial: Correlation of NCCT ASPECT Scores by Individual Region with 90 day MRS in Patients with Successful Reprofusion

Objectives. Invasion of differentiated thyroid cancer (DTC) into surrounding structures can lead to morbid procedures such as laryngectomy and tracheal resection. In these patients, there is a potential role for neoadjuvant therapy.Methods. We identified three studies involving the treatment of DTC with neoadjuvant chemotherapy: two from Slovenia and one from Japan.Results. These studies demonstrate that in selected situations, neoadjuvant chemotherapy can have a good response and allow for a more complete surgical resection, the treatment of DTC. Additionally, the SELECT trial shows that the targeted therapy lenvatinib is effective in the treatment of DTC and could be useful as neoadjuvant therapy for this disease due to its short time to response. Pazopanib has also demonstrated promise in phase II data.Conclusions. Thus, chemotherapy in the neoadjuvant setting could possibly be useful for managing advanced DTC. Additionally, some of the new tyrosine kinase inhibitors (TKIs) hold promise for use in the neoadjuvant setting in DTC.

Download Full-text

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial

Head and neck tumors (HNT) ◽

10.17650/2222-1468-2018-8-2-39-52 ◽

2018 ◽

Vol 8 (2) ◽

pp. 39-52

Author(s):

M. S. Brose ◽

F. P. Worden ◽

K. L. Newbold ◽

M. Guo ◽

A. Hurria

Keyword(s):

Thyroid Cancer ◽

Differentiated Thyroid Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Select Trial ◽

Effect Of Age

.

Download Full-text

RE: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/dju019 ◽

2014 ◽

Vol 106 (4) ◽

pp. dju019-dju019 ◽

Cited By ~ 5

Author(s):

W. S. Harris ◽

M. H. Davidson

Keyword(s):

Prostate Cancer ◽

Fatty Acids ◽

Cancer Risk ◽

Prostate Cancer Risk ◽

Plasma Phospholipid ◽

Phospholipid Fatty Acids ◽

Select Trial

Download Full-text

Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT

Prostate Cancer and Prostatic Diseases ◽

10.1038/s41391-019-0181-y ◽

2019 ◽

Vol 23 (2) ◽

pp. 333-342

Author(s):

Mahbubl Ahmed ◽

◽

Chee Goh ◽

Edward Saunders ◽

Clara Cieza-Borrella ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Susceptibility ◽

Risk Scores ◽

Polygenic Risk Score ◽

Logistic Regression Models ◽

Prostate Cancer Susceptibility ◽

Develop Prostate Cancer ◽

Risk Snps ◽

Chemoprevention Agent ◽

Select Trial

Abstract Background The development of prostate cancer can be influenced by genetic and environmental factors. Numerous germline SNPs influence prostate cancer susceptibility. The functional pathways in which these SNPs increase prostate cancer susceptibility are unknown. Finasteride is currently not being used routinely as a chemoprevention agent but the long term outcomes of the PCPT trial are awaited. The outcomes of the SELECT trial have not recommended the use of chemoprevention in preventing prostate cancer. This study investigated whether germline risk SNPs could be used to predict outcomes in the PCPT and SELECT trial. Methods Genotyping was performed in European men entered into the PCPT trial (n = 2434) and SELECT (n = 4885). Next generation genotyping was performed using Affymetrix® Eureka™ Genotyping protocols. Logistic regression models were used to test the association of risk scores and the outcomes in the PCPT and SELECT trials. Results Of the 100 SNPs, 98 designed successfully and genotyping was validated for samples genotyped on other platforms. A number of SNPs predicted for aggressive disease in both trials. Men with a higher polygenic score are more likely to develop prostate cancer in both trials, but the score did not predict for other outcomes in the trial. Conclusion Men with a higher polygenic risk score are more likely to develop prostate cancer. There were no interactions of these germline risk SNPs and the chemoprevention agents in the SELECT and PCPT trials.

Download Full-text

Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial)

British Journal of Surgery ◽

10.1002/bjs.11117 ◽

2019 ◽

Vol 106 (4) ◽

pp. 355-363 ◽

Cited By ~ 14

Author(s):

G. S. A. Abis ◽

H. B. A. C. Stockmann ◽

H. J. Bonjer ◽

N. van Veenendaal ◽

M. L. M. van Doorn-Schepens ◽

...

Keyword(s):

Colorectal Cancer ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Digestive Tract ◽

Selective Decontamination ◽

Cancer Surgery ◽

Colorectal Cancer Surgery ◽

Select Trial

Download Full-text

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Thyroid ◽

10.1089/thy.2016.0549 ◽

2017 ◽

Vol 27 (9) ◽

pp. 1135-1141 ◽

Cited By ~ 14

Author(s):

Naomi Kiyota ◽

Bruce Robinson ◽

Manisha Shah ◽

Ana O. Hoff ◽

Matthew H. Taylor ◽

...

Keyword(s):

Thyroid Cancer ◽

Differentiated Thyroid Cancer ◽

Efficacy And Safety ◽

Select Trial

Download Full-text

The high-dose aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4514 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4514-4514 ◽

Cited By ~ 52

Author(s):

D. F. McDermott ◽

M. S. Ghebremichael ◽

S. Signoretti ◽

K. A. Margolin ◽

J. Clark ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

High Dose ◽

Select Trial

Download Full-text

Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.4521 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 4521-4521 ◽

Cited By ~ 4

Author(s):

Alexandra S. Bailey ◽

SuChun Cheng ◽

Eugene D. Kwon ◽

Bradley C. Leibovich ◽

Sabina Signoretti ◽

...

Keyword(s):

Tumor Tissue ◽

Tissue Expression ◽

Current Data ◽

Response To Treatment ◽

Antiangiogenic Therapies ◽

Programmed Death ◽

Immune Therapies ◽

Aggressive Histology ◽

Select Trial ◽

Background Expression

4521 Background: Expression of PDL1 by RCC has been associated with aggressive histology and poor survival. Tissue obtained from the patients enrolled in the IL-2 Select Trial, a prospective, single arm, multicenter CWG study, was analyzed by IHC to determine if PDL1or PDL3 expression predicted for response to initial or subsequent therapy. Methods: Paraffin embedded tumor tissue was stained for PDL1 and PDL3 expression, and results were correlated with RECIST defined response to IL2 treatment. Tumor tissue was considered positive for PDL1 if >5% of the tumor membranes stained for the marker. A cutoff of 10% was used for PDL3. Duration of subsequent VEGFR/mTOR inhibitor therapy was also correlated with tissue PDL1/3 expression. Results: 120 eligible pts were enrolled; 115 had clear cell histology. The overall response rate (ORR) to IL2 was 25% (30/120) with a median OS of 40.6 months. 113 tumors were stained. 18 (16%) were PDL1+. ORR was 19% and 50% in the patients PDL1- and PDL1+ tumors, respectively (p=0.012). 85 (75%) tumors were PDL3+. ORR was 10.7% and 29.4% in the PDL3- and PDL3+ tumors, respectively (p=0.075). In the 17 patients who were positive for both PDL1 and PDL3, ORR was 52.9%. In the 27 pts who were negative for both PDL1 and PDL3, ORR was 11.1%. 69 patients received at least 1 dose of a VEGFR TKI as next therapy following IL2 treatment. 66 tumors were stained. Pts who were PDL1+/PDL3+ had a shorter duration on VEGFR TKI therapy compared to pts who were PDL1-/PDL3- (see Table). Conclusions: This small, retrospective analysis suggests that PDL1 and PDL3 tissue expression may predict for better response to IL2. PDL1 expression has been suggested as a possible predictor of response to anti-PD1 therapy. The current data suggests that its expression may predict for benefit to other immune therapies. PDL3 (+/- PDL1) expression appears to correlate to less benefit from subsequent VEGFR TKI therapy. Funded by NCI SPORE Grant # 5 P50 CA101942-08. [Table: see text]

Download Full-text

Molecular marker assessments for epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) and histoscore (H-score) in the phase III SELECT trial.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.8052 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 8052-8052

Author(s):

Edward S. Kim ◽

Sreenivas Chittoor ◽

Craig H. Reynolds ◽

Lorinda Simms ◽

Scott Saxman

Keyword(s):

Growth Factor Receptor ◽

Progression Free Survival ◽

Clinical Results ◽

Phase Iii ◽

Egfr Expression ◽

Phase Iii Study ◽

Previously Treated Patients ◽

Previously Treated ◽

Epidermal Growth ◽

Select Trial

8052 Background: SELECT was a phase III study that investigated whether the addition of cetuximab (C) to pemetrexed (P) improved outcome in previously treated patients (pts) with recurrent or progressive non-small cell lung cancer (NSCLC). Clinical results have been reported previously and demonstrated that adding C to P did not improve progression-free survival (PFS) or overall survival (OS). H-score has been reported to be a potential predictor of outcome for C therapy. Prespecified biomarker analyses, including EGFR IHC and H-score, are reported here. Methods: EGFRexpression in tumor tissue was not required for eligibility; however, tissue was collected and analyzed for EGFR expression by IHC using standard methods. In addition, H-score evaluation was performed by trained central pathologists and correlated with clinical outcome using a predefined cutoff for “low” and “high” of <200 and ≥200, respectively. Results: A total of 449 (IHC) and 406 (H-score) pt specimens were evaluable. Demographics for pts with tissue available for EGFR analysis were similar to the overall population. For IHC+ pts (n=396), median PFS for C+P was 3.02 months (95% CI, 2.76–3.45) compared with 2.99 months (95% CI, 2.63–4.14) for P (HR, 1.02 [95% CI, 0.83–1.24]; p=.86). For pts with low H-score (N=99 [C+P] and N=111 [P]), median PFS was 2.7 months (95% CI, 1.8–3.2) with C+P and 3.1 months (95% CI, 2.6–4.1) with P (HR, 1.11 [95% CI, 0.84–1.46]; P=.48); median OS was 6.7 months (95% CI, 5.3–8.6) with C+P and 6.6 months (95% CI, 4.7–9.2) with P (HR, 0.96 [95% CI, 0.72–1.27]; P=.76). Among pts with high H-scores (N=101 [C+P] and N= 95 [P]), median PFS was 3.2 months (95% CI, 2.7–4.6) with C+P and 3.7 months (95% CI, 1.7–4.5) with P (HR, 1.02 [95% CI, 0.77–1.37]; P=.86); median OS was 7.7 months (95% CI, 6.5–10.9) with C+P and 8.0 months (95% CI, 7.0–9.1) with P (HR, 1.17 [95% CI, 0.86–1.57]; P=.32). Conclusions: EGFR H-score was not predictive of benefit for the addition of C to P in this population of pts with NSCLC. There was also no treatment effect in the IHC+ group. Clinical trial information: NCT00095199.

Download Full-text